Ketamine, TMS, Psychedelics & Neuroplasticity: What the Evidence Shows
Ketamine, TMS and classic psychedelics are often grouped as plasticity-based treatments. Their clinical evidence differs greatly, and so does their regulatory status. Plasticity mechanisms are the leading explanation for several of them, but in humans the chain from molecular or network change to clinical improvement is not established. This page is educational and is not treatment advice.
What plasticity research does and does not tell us about ketamine, esketamine, TMS and psychedelics, with regulation separated from mechanism.
Clinical benefit and plasticity mechanism are two different questions. This article keeps them apart.
Key takeaways
- Two separate questions: does a treatment help, and does plasticity explain why it helps. Evidence differs for each. [3][7]
- Esketamine nasal spray is FDA-approved with specific labeled indications and a REMS; racemic ketamine for depression is off-label; compounded ketamine products carry FDA-flagged risks. [1][2][5]
- TMS devices are FDA-cleared or authorised for specific indications through device pathways, not blanket approvals, and the depression evidence base is substantial. [8][9][10][11]
- As of August 2026, no classic psychedelic is FDA-approved for a psychiatric indication; several remain investigational. [17]
- The most direct synaptic evidence for all three comes from cells and rodents. Human work is largely indirect. [6][24][25][28]
- More plasticity is not automatically better. A more changeable brain may be more sensitive to experience in either direction. [30]
Why these treatments get discussed together
Ketamine, transcranial magnetic stimulation and classic psychedelics such as psilocybin are very different things: an anaesthetic-derived drug, a magnetic stimulation device, and a serotonergic compound. They are grouped together because researchers proposed a shared idea, that each may change the brain's capacity for adaptive change rather than simply adjusting a neurotransmitter level day after day. [7][30]
That shared framing is genuinely interesting, and it is also where overstatement creeps in. A shared hypothesis is not shared evidence. Each of these interventions has its own clinical literature, its own regulatory status and its own strength of plasticity data, and mixing them produces claims that none of them individually supports.
Throughout this article, seven questions are kept separate: does the intervention improve clinical outcomes; is it legally authorised for that use; what mechanism is proposed; what plasticity evidence exists; is that evidence human, preclinical or indirect; does the mechanism explain the clinical benefit; and what remains unknown.
The distinction that matters most: Clinical efficacy and neuroplasticity mechanism are different questions. A treatment can work without anyone knowing why. A striking cellular plasticity finding can be real and still tell you nothing about whether a person will get better.
Ketamine and esketamine: three different things
Public discussion uses "ketamine" as one word for at least three distinct situations, and the evidence and the law differ for each. Esketamine (the S-enantiomer) is marketed as a nasal spray with FDA-approved labeling. Racemic ketamine, the generic anaesthetic, is used off-label for depression, most often intravenously. Compounded ketamine products, including troches and nasal sprays prepared outside an approved manufacturing process, are a third category with its own risks. [1][5]
On efficacy in depression: a large randomised non-inferiority trial in non-psychotic treatment-resistant depression found intravenous ketamine non-inferior to electroconvulsive therapy on response, in patients referred for ECT. [4] An earlier consensus statement from mood-disorder specialists concluded the antidepressant evidence for ketamine was promising but that questions of dosing, maintenance, longer-term safety and appropriate settings were unresolved. [3] The rapid onset is a real and replicated observation; durability after a single exposure is the weaker part of the picture. [3][4]
On the risks the label itself emphasises: sedation, dissociation, respiratory depression, abuse and misuse, and increased risk of suicidal thoughts and behaviours in paediatric and young adult patients taking antidepressants, with monitoring after administration. [1] Blood-pressure increases and the need for supervised administration are part of why these products are given in certified settings rather than at home. [1][2][3]
Beiing does not provide dosing information, route comparisons or candidacy advice, and does not endorse at-home or direct-to-consumer ketamine programmes. Those are clinical decisions that require a qualified prescriber working in an appropriately regulated setting.
- Racemic ketamine: a generic anaesthetic used off-label for depression, mostly intravenously, in supervised settings. [3][4]
- Esketamine nasal spray: an FDA-approved product with labeled indications, a boxed warning and a restricted distribution programme. [1][2]
- Compounded ketamine products: not FDA-approved products; the FDA maintains compounding risk alerts covering risks associated with such products. [5]
Regulatory reality: approval, off-label use and compounding
Approved product and labeled indication. Esketamine nasal spray (SPRAVATO) is a Schedule III non-competitive NMDA receptor antagonist indicated in adults for treatment-resistant depression, as monotherapy or in conjunction with an oral antidepressant, and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behaviour, in conjunction with an oral antidepressant. The label states that effectiveness in preventing suicide or in reducing suicidal ideation has not been demonstrated, and that use as anaesthesia has not been established. It carries a boxed warning and is available only through a restricted programme, the SPRAVATO REMS, with monitoring for at least two hours after administration. [1][2]
Off-label use. Intravenous racemic ketamine for depression is off-label prescribing: a clinician using an approved drug for an unapproved indication. Off-label does not mean illegal, and it does not mean ineffective; it means the FDA has not reviewed and approved that specific use, so the safeguards attached to an approved indication - labeled dosing, required monitoring, a REMS - do not automatically apply. Professional consensus guidance exists precisely because of that gap. [3]
Compounded products. Compounded ketamine preparations are not FDA-approved drugs and have not been evaluated by the FDA for safety, effectiveness or quality. The FDA publishes compounding risk alerts covering risks associated with compounded products, including those used outside supervised health-care settings. [5]
Common clinical use is not the same as approval, and approval of one product does not extend to another product, route or formulation.
Regulatory reality box: FDA-approved product with a labeled indication (esketamine nasal spray, with REMS) is not the same as off-label prescribing of racemic ketamine, which is not the same as a compounded ketamine product, which is not the same as investigational use inside a clinical trial. Four different things, four different levels of oversight. [1][2][3][5]
What plasticity evidence exists for ketamine
The mechanistic account runs roughly like this: NMDA receptor antagonism produces a burst of glutamate signalling, favouring AMPA receptor-mediated transmission, engaging BDNF/TrkB and mTOR-related signalling, and increasing synaptic proteins and dendritic spine formation in prefrontal circuits. That cascade is well described in rodents and in cellular preparations, and it is the dominant explanatory framework in the field. [7]
In humans, the picture is thinner and more interesting. A PET study using the SV2A radioligand [11C]UCB-J, an index of synaptic terminal density, found no measurable effect on synaptic density 24 hours after a single ketamine administration in non-human primates, healthy controls, or people with depression or PTSD - despite a robust reduction in symptoms. An exploratory post-hoc analysis suggested that participants with lower baseline synaptic density might show an increase, correlated with symptom reduction, and the authors called for replication in a larger sample. [6]
Read that carefully, because it is the crux of the whole article. Symptoms improved without a detectable group-level change in the plasticity marker the theory predicts. That does not disprove the synaptic hypothesis - the measure is indirect, the timing may be wrong, and terminal density is not the same as spine remodelling - but it does mean the human causal chain is not established. [6][7]
So the accurate statement is: synaptic-plasticity mechanisms are the leading explanation for ketamine's rapid antidepressant effects, but the causal chain from molecular changes to clinical recovery in humans is not fully established. The inaccurate statement is that ketamine grows new synapses in depressed people, or that it works because it rewires the brain.
TMS: what it is, and what the regulators actually authorised
Transcranial magnetic stimulation is non-invasive: a coil held against the scalp generates rapidly changing magnetic fields that induce electrical currents in targeted cortical tissue. [16] It is not one thing. Conventional high-frequency repetitive TMS, deep TMS using differently shaped coils, intermittent theta burst stimulation (iTBS), and accelerated protocols delivering many sessions per day differ in pulse pattern, targeting and evidence base, and should not be treated as interchangeable. [12][13][14]
Terminology matters here. TMS systems are regulated as devices, not drugs. Repetitive transcranial magnetic stimulation systems for major depressive disorder are a Class II device type with special controls under 21 CFR 882.5805, and transcranial magnetic stimulation systems for obsessive compulsive disorder are classified separately under 21 CFR 882.5802. [8][9] Individual devices reach the market through clearance or authorisation for a specific indication - for example, the Magnus Neuromodulation System with SAINT Technology, an accelerated iTBS system, was cleared in 2022 with an indication for major depressive disorder in adults who have not achieved satisfactory improvement from prior antidepressant medication in the current episode. [10]
So "FDA-cleared for a specific indication, on a specific device" is correct; "FDA-approved TMS" as a blanket phrase is not. Clearance also rests on substantial equivalence to a predicate device, which is a different evidentiary standard from drug approval.
Clearance is device-specific: A clearance attaches to a named device with a named indication, coil and protocol. It does not certify every clinic, coil, schedule or condition that uses the word TMS. [8][9][10]
TMS clinical evidence, independent of any mechanism
TMS for depression has a substantial randomised evidence base. A network meta-analysis of non-surgical brain stimulation for acute major depressive episodes found several rTMS protocols more effective than sham on response and remission. [11] A large randomised non-inferiority trial found iTBS non-inferior to standard 10 Hz rTMS while taking a fraction of the session time, which changed routine practice. [12] A double-blind randomised trial of an accelerated, imaging-targeted theta-burst protocol reported high remission rates in treatment-resistant depression in a small sample, an encouraging result that later work will need to reproduce at scale. [13]
This is the cleanest illustration of the article's central point. TMS has clinical evidence for depression whether or not any particular plasticity mechanism turns out to explain it. Efficacy evidence and mechanism evidence are gathered by different studies and stand or fall independently. [11][14]
Beiing does not advise on intensity, motor threshold, coil placement, session counts, accelerated schedules or individual candidacy. For a general overview of what TMS treatment involves, see our TMS therapy page; for treatment decisions, see a qualified clinician.
Why TMS is described in plasticity terms
Single pulses and repetitive trains change cortical excitability measurably, and the direction depends on frequency and pattern. Theta-burst patterns were designed from LTP-like and LTD-like induction protocols in animal preparations, which is why the language of long-term potentiation and depression is used. [12][15] Repeated stimulation is also thought to shift excitation-inhibition balance and network connectivity, and effects are state-dependent and vary with the individual's neurobiology. [14][15]
What does not follow is that a course of clinical TMS literally rewires one depression circuit. Neurophysiological effects differ by frequency, pulse pattern, target, intensity, brain state and person, and the mechanism mediating antidepressant response remains incompletely established. [14][15] A person responding to TMS is not evidence that a particular proposed plasticity mechanism occurred in that person.
TMS safety, stated from consensus evidence
Expert safety guidelines describe TMS as generally well tolerated when applied within recommended parameters, with common transient effects including scalp discomfort and headache, and recommend hearing protection because of the coil's acoustic artefact. Seizure is the main serious risk and is uncommon; screening covers factors such as seizure history, medications that lower seizure threshold, and implanted or ferromagnetic devices near the coil. [15]
Treatment-emergent mania or hypomania is a recognised consideration in people with bipolar disorder and is part of clinical screening and monitoring. [14][15] Isolated adverse-event reports should not be converted into incidence estimates; consensus and systematic sources are the right basis for risk statements. [15]
Classic psychedelics: current regulatory status first
As of August 2026, no classic psychedelic is FDA-approved for any psychiatric indication in the United States. Psilocybin remains investigational: it is studied under investigational new drug applications, and regulatory activity such as a rolling submission, breakthrough therapy designation, a priority review voucher or an accepted application is not approval. Those designations affect how and how fast an application is reviewed; they say nothing final about whether a product will be approved or how well it works. [17]
In July 2026 the FDA issued the final version of its guidance, Psychedelic Drugs: Considerations for Clinical Investigations, updating the 2023 draft. Guidance describes how to study a drug class. It is not an endorsement of efficacy and it is not an approval. [17]
MDMA (midomafetamine) is usually classed as an entactogen rather than a classic serotonergic psychedelic, and it is included in the same regulatory conversation because it is developed under the same framework. It is not FDA-approved for PTSD or any psychiatric indication; a Complete Response Letter was issued in 2024, and subsequent regulatory activity does not constitute approval. [17] Beyond that, MDMA is outside this article's focus.
Legal status is separate again: state-level supervised-use frameworks or decriminalisation measures are not federal approval and are not evidence of efficacy.
These are not equivalent: Breakthrough therapy designation, orphan designation, priority review, a priority voucher, permission to run a trial, expanded access, and approval are seven different things. Only the last means a product may be marketed for that use. [17]
Why psychedelic trials are unusually hard to interpret
FDA's guidance for this class exists because the standard trial toolkit strains here. Participants can usually tell whether they received an active dose, so functional unblinding is close to unavoidable; expectancy is high in a field with strong public narratives; and the drug is typically given alongside substantial psychological support, which makes it hard to attribute outcomes to the molecule alone. The guidance also addresses safety monitoring, the role of the therapy component, abuse potential assessment, dose-response characterisation and durability of effect. [17]
Independent methodologists have made the same point sharply: blinding failure and expectancy can inflate apparent effect sizes in psychedelic trials, and standard placebo-controlled inference may not hold in the usual way. [23] This is a reason for care in reading results, not a reason to dismiss them.
Psilocybin: what the clinical trials show, read conservatively
Randomised evidence in depression is real and reasonably consistent in the short term. A phase 2 dose-ranging trial in treatment-resistant depression, with psychological support, found a single 25 mg dose reduced depression scores at three weeks more than a 1 mg comparator, with a substantial proportion not sustaining response at twelve weeks and with serious adverse events reported in each dose group. [18] A randomised trial in major depressive disorder found a single dose associated with sustained symptom reduction over six weeks compared with an active placebo. [19] A head-to-head phase 2 trial against escitalopram found no significant difference on the primary depression measure, with secondary measures generally favouring psilocybin, and the authors cautioned that the trial was not powered for that comparison. [20]
A dose-response network meta-analysis of randomised placebo-controlled trials synthesised this literature to inform dose and timing decisions for further development, which is a fair summary of where the field is: promising enough to design confirmatory programmes around, not settled. [21]
The limitations are not footnotes. Trial populations have been relatively small and highly selected, typically excluding psychosis, bipolar disorder and significant medical risk. Blinding is difficult to maintain. [23] Intensive preparation, monitoring and integration sessions accompany dosing, so the drug and the context are hard to separate. Comparators vary between trials. Long-term durability and long-term safety data remain limited. [18][20][21]
Psilocybin is not a proven replacement for established depression treatment, and nothing here supports self-treatment. Unsupervised use carries real risks, including psychological distress and harm in people vulnerable to psychosis or mania. A meta-analysis of adverse events in classic psychedelic studies provides a more systematic basis for risk discussion than anecdote in either direction. [22]
Psychedelics and plasticity: strong findings, mostly not in humans
The preclinical literature here is genuinely strong. Serotonergic psychedelics promote dendritic growth, spine formation and synapse number in cultured neurons and in rodents, with effects dependent on TrkB and mTOR signalling. [24] Two-photon imaging in living mice showed psilocybin producing rapid and persistent growth of dendritic spines in frontal cortex. [25] Later work reported that psychedelics bind directly to the BDNF receptor TrkB, [26] and that plasticity-promoting effects depend on activation of intracellular rather than surface 5-HT2A receptors - which also helps explain why some non-hallucinogenic compounds can produce similar cellular changes. [27]
Human evidence is a different category. It measures networks, not synapses. Psilocybin desynchronises large-scale cortical networks during the acute experience, with a persisting change in one network detectable for weeks in a small precision-imaging study. [28] In depression trials, imaging has shown increased global brain-network integration after psilocybin therapy. [29] These are network-level findings, and describing them as direct observation of synaptogenesis in the human brain would be wrong.
So: evidence strength strong, context primarily preclinical, for the structural plasticity claims. Evidence strength emerging, context human, for the network claims. Neither yet demonstrates that a structural plasticity change causes clinical improvement in people.
"Psychoplastogen" and "plasticity window": research terms, not clinical facts
Psychoplastogen was proposed as a label for small molecules that rapidly promote structural and functional neural plasticity after a single administration. [30] Neuroplastogen is used similarly. Metaplasticity refers to plasticity of plasticity: a change in how readily subsequent plastic change can occur. A plasticity window describes a hypothesised period of heightened responsiveness to experience following an intervention.
These are useful research concepts. They are not validated clinical biomarkers, they are not diagnostic categories, and they are not consumer treatment categories. There is no established test that tells an individual their plasticity window is open, and no evidence that a marketed product can reliably open one to therapeutic benefit.
The term has also been adopted in commercial contexts, which is a reason to use it precisely rather than to avoid it. Describing a compound as a psychoplastogen states a hypothesis about cellular mechanism. It does not state that the compound treats any condition.
Does increased plasticity explain who gets better?
This is the question the field has not answered. For a mechanism to be a demonstrated mediator rather than a plausible story, the plasticity change would need to be measured in the people who improved, occur before the improvement, track its size, and ideally be manipulable - block the mechanism, lose the benefit.
Currently: the human ketamine synaptic-density study found symptom improvement without a group-level change in the marker; [6] TMS response is not tied to any confirmed individual plasticity measurement; [14] and psilocybin's human data are network-level with the structural claims resting on animals. [25][28] The mechanistic accounts remain the best available explanations, and they remain unproven as the cause of clinical benefit. [7]
What would actually prove the plasticity hypothesis?
It is worth being concrete about the evidence that would move this from plausible mechanism to demonstrated mediator. Naming the missing pieces is more useful than repeating that more research is needed.
- Validated human measures of the specific plasticity process claimed, not just proxies that could reflect several things. [6]
- A temporal relationship: the plasticity change measurably precedes the clinical improvement in the same individuals. [6]
- A dose-response or target-engagement relationship linking the degree of mechanism engagement to the degree of benefit. [17][21]
- Experimental manipulation: blocking or enhancing the proposed mechanism changes the clinical outcome accordingly. [27]
- Independent replication in larger and less selected samples, with pre-registered analyses. [6][13]
- Separation from nonspecific effects such as expectancy, therapeutic contact and unblinding. [23]
Plasticity windows, environment and therapy: a hypothesis worth stating carefully
One of the most interesting ideas in this field is that these interventions may not make the brain healthier so much as make it more sensitive to experience for a period. In that framework: intervention, then a temporary change in plasticity or network state, then environmental and therapeutic experience, then subsequent learning. The intervention would set conditions; what is learned would depend on what happens next. [7][30]
This is a hypothesis, and the human causal evidence for it is incomplete. It is not established that psychotherapy is biologically required for ketamine to work, and describing psychedelic-assisted therapy simply as rewiring during a window overstates what anyone has shown. Trials do provide psychological support alongside dosing, which is a design fact rather than a demonstration of mechanism. [18][19][20]
The hypothesis also cuts both ways. A heightened capacity for learning is not intrinsically therapeutic; it could support adaptive change or maladaptive change depending on context. That is the same logic explored in our article on when plasticity works against a person.
Evidence matrix: how the three compare, honestly
This is a comparison of evidence, not a ranking of treatments, and none of it indicates what any individual should do.
- Ketamine / esketamine - Clinical evidence: moderate to strong for specific depressive uses depending on product and route, with durability less well established. [3][4] Regulatory status: esketamine nasal spray FDA-approved with labeled indications, boxed warning and REMS; racemic ketamine off-label; compounded products not FDA-approved. [1][2][5] Direct human plasticity evidence: limited and indirect; a PET synaptic-density study found no group-level change alongside symptom improvement. [6] Preclinical plasticity evidence: strong. [7] Major uncertainty: whether synaptic mechanisms mediate the clinical effect in people. [6][7]
- TMS - Clinical evidence: strong for depression across randomised trials and network meta-analysis. [11][12] Regulatory status: device pathway; specific systems cleared or authorised for specific indications under 21 CFR 882.5805 and 882.5802. [8][9][10] Direct human plasticity evidence: cortical excitability changes are measurable in humans, but link to clinical response is unconfirmed. [14][15] Preclinical plasticity evidence: LTP/LTD-like induction well characterised in animal preparations. [12][15] Major uncertainty: which neurophysiological change, if any, mediates antidepressant response. [14]
- Classic psychedelics / psilocybin - Clinical evidence: emerging to moderate; several positive randomised trials in depression with real methodological limits. [18][19][20][21][23] Regulatory status: investigational; no classic psychedelic FDA-approved for a psychiatric indication as of August 2026; final FDA clinical-investigation guidance issued 2026. [17] Direct human plasticity evidence: network-level imaging changes, not observed synaptogenesis. [28][29] Preclinical plasticity evidence: strong, including spine growth and TrkB and intracellular 5-HT2A mechanisms. [24][25][26][27] Major uncertainty: separating drug effects from context, durability, and whether plasticity mediates outcome. [21][23]
Risks and boundaries
Each of these carries real risk, and risk statements should come from labels and consensus documents rather than enthusiasm. For esketamine: sedation, dissociation, respiratory depression, abuse and misuse potential, blood-pressure effects, and the monitoring requirements that follow from them. [1][2] For racemic ketamine used off-label, professional consensus flags unresolved questions about longer-term safety, maintenance treatment and appropriate settings. [3] For TMS: transient discomfort and headache, hearing protection, uncommon seizure risk, and screening for mania risk and device contraindications. [15] For classic psychedelics: acute psychological distress, cardiovascular effects, and exclusion criteria used in trials for good reason, with systematic adverse-event synthesis a better guide than anecdote. [22]
For controlled and investigational substances, Beiing does not provide guidance on obtaining or using them outside regulated settings. Treatment decisions belong with qualified clinicians. If you are in crisis or worried about your immediate safety, see Beiing's Crisis Resources page for verified urgent support options.
What we know
- Esketamine nasal spray has FDA-approved labeled indications in treatment-resistant depression and in depressive symptoms with acute suicidal ideation or behaviour, with a boxed warning, REMS and post-dose monitoring. [1][2]
- Intravenous racemic ketamine for depression is off-label and was found non-inferior to ECT in one large randomised trial of referred patients. [3][4]
- TMS has a substantial randomised evidence base for depression, and iTBS is non-inferior to standard rTMS. [11][12]
- TMS devices are cleared or authorised individually for specific indications under device regulations, not approved as a general therapy. [8][9][10]
- No classic psychedelic is FDA-approved for a psychiatric indication as of August 2026; FDA finalised its clinical-investigation guidance for the class in 2026. [17]
- Psychedelics produce robust structural plasticity in cells and rodents, including via TrkB and intracellular 5-HT2A mechanisms. [24][25][26][27]
What we are still learning
- Whether plasticity changes mediate clinical improvement in humans for any of these interventions. [6][7][14]
- Whether the exploratory finding that people with lower baseline synaptic density respond differently to ketamine replicates. [6]
- Which TMS protocol parameters matter mechanistically, and for whom. [12][13][14]
- How much of psilocybin's trial benefit reflects the drug versus expectancy, unblinding and intensive psychological support. [20][23]
- Long-term durability and long-term safety across all three, especially with repeated exposure. [3][18][21]
- Whether heightened plasticity is beneficial, neutral or harmful depending on what a person experiences next. [30]
Cautions
- This article is educational. It is not medical advice, and it contains no dosing, protocol or candidacy guidance by design.
- Common clinical use does not equal FDA approval, and off-label prescribing is neither illegal nor proof of effectiveness.
- Compounded ketamine products are not FDA-approved and are covered by FDA compounding risk alerts. [5]
- Do not use controlled substances outside regulated, supervised settings; unsupervised psychedelic use carries real psychological and medical risk. [22]
- Preclinical plasticity findings in cells and rodents do not establish that the same structural changes occur in the living human brain. [24][25]
- If you are in crisis, use Beiing's Crisis Resources page rather than waiting for a research answer.
Frequently asked questions
Does ketamine increase neuroplasticity?
In animals and cell models, yes - glutamatergic, BDNF/TrkB and mTOR-linked mechanisms increase synaptic proteins and dendritic spines. In humans the evidence is indirect: a PET study of synaptic density found no measurable group-level change 24 hours after a single dose despite symptoms improving, with only an exploratory signal in people with low baseline density. Plasticity is the leading explanation, not a demonstrated one. [6][7]
Does TMS rewire the brain?
Not in the way the phrase suggests. TMS measurably changes cortical excitability and is designed around LTP-like and LTD-like induction patterns, and it has strong clinical evidence for depression. But which neurophysiological change mediates the antidepressant response is not established, and responding to TMS does not prove any specific circuit was remodelled. [11][14][15]
Does psilocybin increase neuroplasticity?
In rodents and cultured neurons the structural evidence is strong, including rapid dendritic spine growth and TrkB-dependent mechanisms. In humans, studies show network-level changes such as cortical desynchronisation and increased global integration - not direct observation of new synapses. The species distinction is the whole point. [25][26][28][29]
What is a psychoplastogen?
A research term for a small molecule that rapidly promotes structural and functional neural plasticity after a single administration. It describes a hypothesised cellular mechanism, not a proven clinical category, and it does not mean a compound treats any condition. [30]
What is a plasticity window?
A hypothesised period after an intervention when the brain may be more responsive to experience. It is a research framework rather than something clinicians can currently measure in an individual, and no test tells you whether yours is open.
Is more neuroplasticity always beneficial?
No. Greater capacity for change is not intrinsically therapeutic; the same mechanisms support unhelpful learning as helpful learning. Whether increased plasticity helps may depend heavily on what a person experiences during that period, which remains a hypothesis in humans. [30]
Does neuroplasticity explain how antidepressant treatments work?
It is the leading mechanistic framework for rapid-acting treatments, and it has not been shown to be the mediator of clinical benefit in people. A treatment can have good efficacy evidence while its mechanism stays unsettled, which is currently true of TMS and arguably of ketamine. [4][7][11]
Is esketamine the same as ketamine?
No. Esketamine is one enantiomer, marketed as a nasal spray with FDA-approved indications, a boxed warning and a restricted distribution programme. Racemic ketamine is the generic anaesthetic used off-label for depression. Compounded ketamine products are a third, unapproved category. Evidence and oversight differ across all three. [1][2][3][5]
Related on Beiing
- TMS Therapy - Our general overview of what TMS treatment involves.
- Ketamine Therapy - The broader treatment overview, separate from mechanism.
- Psilocybin Research - Background on psilocybin studies and legal context.
- Depression & Neuroplasticity - Why mechanism and efficacy must be kept apart.
- Can Neuroplasticity Be Harmful? - Why more plasticity is not automatically better.
- BDNF: What It Is and What the Evidence Shows - A molecule central to these mechanisms, read carefully.
- Crisis Resources - Verified urgent support options if you need help now.
Sources
- SPRAVATO (esketamine) nasal spray, CIII - current full prescribing information (label revised 2026) - DailyMed / FDA-approved labeling, Janssen Pharmaceuticals, 2026
- SPRAVATO REMS (Risk Evaluation and Mitigation Strategy) - SPRAVATO REMS Program
- A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders - Sanacora G, Frye MA, McDonald W, et al., JAMA Psychiatry, 2017
- Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression - Anand A, Mathew SJ, Sanacora G, et al., New England Journal of Medicine, 2023
- Compounding Risk Alerts (including compounded ketamine products) - U.S. Food and Drug Administration
- Imaging the effect of ketamine on synaptic density (SV2A) in the living brain - Holmes SE, Finnema SJ, Naganawa M, et al., Molecular Psychiatry, 2022
- Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants - Kadriu B, Greenwald M, Henter ID, et al., International Journal of Neuropsychopharmacology, 2021
- 21 CFR 882.5805 - Repetitive transcranial magnetic stimulation system (Class II) - U.S. Food and Drug Administration, Code of Federal Regulations
- 21 CFR 882.5802 - Transcranial magnetic stimulation system for obsessive compulsive disorder - U.S. Food and Drug Administration, Code of Federal Regulations
- 510(k) K220177 - Magnus Neuromodulation System with SAINT Technology (accelerated intermittent theta burst stimulation) - U.S. Food and Drug Administration, 510(k) Premarket Notification database, 2022
- Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis - Mutz J, Vipulananthan V, Carter B, Hurlemann R, Fu CHY, Young AH, BMJ, 2019
- Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial - Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al., The Lancet, 2018
- Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial - Cole EJ, Phillips AL, Bentzley BS, et al., American Journal of Psychiatry, 2022
- Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression - McClintock SM, Reti IM, Carpenter LL, et al., Journal of Clinical Psychiatry, 2018
- Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines - Rossi S, Antal A, Bestmann S, et al., Clinical Neurophysiology, 2021
- Brain Stimulation Therapies - National Institute of Mental Health (NIMH), NIH
- Psychedelic Drugs: Considerations for Clinical Investigations - Guidance for Industry (final) - U.S. Food and Drug Administration, CDER, 2026
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression - Goodwin GM, Aaronson ST, Alvarez O, et al., New England Journal of Medicine, 2022
- Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial - Raison CL, Sanacora G, Woolley J, et al., JAMA, 2023
- Trial of Psilocybin versus Escitalopram for Depression - Carhart-Harris R, Giribaldi B, Watts R, et al., New England Journal of Medicine, 2021
- Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials - Swieczkowski D, Kwiatkowska K, Jaguszewski MJ, et al., Psychiatry Research, 2025
- Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis - Hinkle JT, Graziosi M, Nayak SM, Yaden DB, JAMA Psychiatry, 2024
- Blinding and expectancy confounds in psychedelic randomized controlled trials - Muthukumaraswamy SD, Forsyth A, Lumley T, Expert Review of Clinical Pharmacology, 2021
- Psychedelics Promote Structural and Functional Neural Plasticity - Ly C, Greb AC, Cameron LP, et al., Cell Reports, 2018
- Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo - Shao LX, Liao C, Gregg I, et al., Neuron, 2021
- Psychedelics promote plasticity by directly binding to BDNF receptor TrkB - Moliner R, Girych M, Brunello CA, et al., Nature Neuroscience, 2023
- Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors - Vargas MV, Dunlap LE, Dong C, et al., Science, 2023
- Psilocybin desynchronizes the human brain - Siegel JS, Subramanian S, Perry D, et al., Nature, 2024
- Increased global integration in the brain after psilocybin therapy for depression - Daws RE, Timmermann C, Giribaldi B, et al., Nature Medicine, 2022
- Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics - Olson DE, Journal of Experimental Neuroscience, 2018
Published ยท Updated
Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.